Jasper M. Bos
Independent DirectorDr. Jasper M. Bos, Ph.D., serves as General Partner at Forbion Capital Partners B.V., which he joined in May 2021. He is Co-Owner of Forbion Growth Sponsor Feac I B.V. He serves as Investor Director & Board Member at CellCentric Ltd since May 2025, Independent Director at Braveheart Bio, Inc. since September 2025, Director at CATALYM GmbH since May 2025, and Director at Engrail Therapeutics, Inc. since March 19, 2024. Dr. Bos also serves as Director at Vaximm AG, Director at Metabomed LTD, Non-Executive Director at Precirix NV, Director at Anaveon AG, and Director at Neviah Genomics. He is a visiting scholar at the University of Groningen. His prior experience includes serving as an Independent Director at enGene Therapeutics Inc. from May 2024 to July 2025 and as its Director from August 8, 2023, to May 2024. He was employed at Merck Ventures B.V. from March 2009 to May 2021, where he served in several roles including Senior Vice President & Managing Director until May 2021, Managing Director from December 31, 2018, Vice President and Head of Healthcare until December 31, 2018, and Senior Director & Vice President. He served as Director at Calypso Biotech SA until 2020. Dr. Bos also served as Chief Executive Officer of Forbion European Acquisition Corp., Director at Damora Therapeutics, Inc., Director at Prexton Therapeutics SA, Director at ObsEva SA, which he joined on August 29, 2013, Chairman of Inthera Bioscience AG, Director at Galecto, Inc., and Director at EpiTherapeutics AS. Previously, he was an Investment Manager at African Health Systems Management and worked as a Health Economics and Strategy Manager at the Netherlands Vaccine Institute. At M Ventures, he led a team of investment professionals and invested in numerous portfolio companies spanning biotech, life sciences tools, and tech companies. His track record includes the successful exits of Prexton Therapeutics, Epitherapeutics, Galecto, ObsEva, Translate Bio, and F-Star. He also played a key role in the creation of multiple successful spin-out companies out of Merck. He has published numerous articles on health economics and vaccines. He holds a Ph.D. in Pharmacy from 2000 to 2003 and an M.S. in Pharmacy from 1993 to 1997, both from Rijksuniversiteit Groningen. He attended the Amsterdam Institute of Finance in 2006.
Positions
- Company NameBraveheart Bio, Inc.Stock CodeBRVEPositionIndependent DirectorColleagues
- TMTravis MurdochCEO, President & Director
- CAChristopher A. ViehbacherIndependent Chairman
- JPJames Paul RickeyChief Financial Officer
- MAMichele A. AndersonChief Development Officer
- MEMarc EvanchikChief Scientific Officer
- NDNatalie DementVP & Head of Legal
- DCDavid Charles LubnerIndependent Director
- ECErez ChimovitsIndependent Director
